|
1
|
Raghu G, Collard HR, Egan JJ, Martinez FJ,
Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et
al: An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary
fibrosis: Evidence-based guidelines for diagnosis and management.
Am J Respir Crit Care Med. 183:788–824. 2011. View Article : Google Scholar :
|
|
2
|
Raghu G, Weycker D, Edelsberg J, Bradford
WZ and Oster G: Incidence and prevalence of idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med. 174:810–816. 2006. View Article : Google Scholar
|
|
3
|
Gribbin J, Hubbard RB, Le Jeune I, Smith
CJ, West J and Tata LJ: Incidence and mortality of idiopathic
pulmonary fi brosis and sarcoidosis in the UK. Thorax. 61:980–985.
2006. View Article : Google Scholar :
|
|
4
|
American Thoracic Society; European
Respiratory Society: American Thoracic Society/European Respiratory
Society International Multidisciplinary Consensus Classification of
the Idiopathic Interstitial Pneumon Society (ERS) was adopted by
the ATS board of directors, June 2001 and by the ERS executive
committee, June 2001. Am J Respir Crit Care Med. 165:277–304.
2002.
|
|
5
|
Henderson WR Jr, Chi EY, Ye X, Nguyen C,
Tien YT, Zhou B, Borok Z, Knight DA and Kahn M: Inhibition of
Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses
pulmonary fibrosis. Proc Natl Acad Sci USA. 107:14309–14314. 2010.
View Article : Google Scholar :
|
|
6
|
Kanai T, Ishiwata T, Kobayashi T, Sato H,
Takizawa M, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N,
Nishiyama M, et al: Ulinastatin, a urinary trypsin inhibitor, for
the initial treatment of patients with Kawasaki disease: A
retrospective study. Circulation. 124:2822–2828. 2011. View Article : Google Scholar
|
|
7
|
Sato H, Kajikawa S, Kuroda S, Horisawa Y,
Nakamura N, Kaga N, Kakinuma C, Kato K, Morishita H, Niwa H and
Miyazaki J: Impaired fertility in female mice lacking urinary
trypsin inhibitor. Biochem Biophys Res Commun. 281:1154–1160. 2001.
View Article : Google Scholar
|
|
8
|
Umeadi C, Kandeel F and Al-Abdullah IH:
Ulinastatin is a novel protease inhibitor and neutral protease
activator. Transplant Proc. 40:387–389. 2008. View Article : Google Scholar
|
|
9
|
Pugia MJ and Lott JA: Pathophysiology and
diagnostic value of urinary trypsin inhibitors. Clin Chem Lab Med.
43:1–16. 2005. View Article : Google Scholar
|
|
10
|
Wang G, Wen J, Wilbur RR, Wen P, Zhou SF
and Xiao X: The effect of somatostatin, ulinastatin and Salvia
miltiorrhiza on severe acute pancreatitis treatment. Am J Med Sci.
346:371–376. 2013. View Article : Google Scholar
|
|
11
|
Wei W, Ma B, Li HY, Jia Y, Lv K, Wang G,
Zhang J, Zhu S, Tang H, Sheng Z and Xia Z: Biphasic effects of
selective inhibition of transforming growth factor beta1 activin
receptor-like kinase on LPS-induced lung injury. Shock. 33:218–224.
2010. View Article : Google Scholar
|
|
12
|
Wang J: Care and Use of Laboratory
Animals. 8th edition. Shanghai Science and Technology Press; 2012,
View Article : Google Scholar
|
|
13
|
O'connor WN and Valle S: A combination
Verhoeffs elastic and Masson's trichrome stain for routine
histology. Stain Technol. 57:207–210. 1982. View Article : Google Scholar
|
|
14
|
Szapiel SV, Elson NA, Fulmer JD,
Hunninghake GW and Crystal RG: Bleomycin-induced interstitial
pulmonary disease in the nude, athymic rat. Am Rev Respir Dis.
120:893–899. 1979.
|
|
15
|
Hakenjos L, Bamberg M and Rodemann HP:
TGF-beta1-mediated alterations of rat lung fibroblast
differentiation resulting in the radiation-induced fibrotic
phenotype. Int J Radiat Biol. 76:503–509. 2000. View Article : Google Scholar
|
|
16
|
Moore BB and Hogaboam CM: Murine models of
pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol.
294:L152–L160. 2008. View Article : Google Scholar
|
|
17
|
King TE Jr, Pardo A and Selman M:
Idiopathic pulmonary fibrosis. Lancet. 378:1949–1961. 2011.
View Article : Google Scholar
|
|
18
|
American Thoracic Society. Idiopathic
pulmonary fibrosis: Idiopathic pulmonary fibrosis: Diagnosis and
treatment. International consensus statement. American Thoracic
Society (ATS), and the European Respiratory Society (ERS). Am J
Resp Crit Care Med. 161:646–664. 2000. View Article : Google Scholar
|
|
19
|
Tobin RW, Pope CE II, Pellegrini CA, Emond
MJ, Sillery J and Raghu G: Increased prevalence of gastroesophageal
reflux in patients with idiopathic pulmonary fibrosis. Am J Resp
Crit Care Med. 158:1804–1808. 1998. View Article : Google Scholar
|
|
20
|
Wang X, Xue Q, Yan F, Li L, Liu J, Li S
and Hu S: Ulinastatin as a neuroprotective and anti-inflammatory
agent in infant piglets model undergoing surgery on hypothermic
low-flow cardiopulmonary bypass. Pediatr Anesth. 23:209–216. 2013.
View Article : Google Scholar
|
|
21
|
Shin IW, Jang IS, Lee SM, Park KE, Ok SH,
Sohn JT, Lee HK and Chung YK: Myocardial protective effect by
ulinastatin via an anti-inflammatory response after regional
ischemia/reperfusion injury in an in vivo rat heart model. Korean J
Anesthesiol. 61:499–505. 2011. View Article : Google Scholar :
|
|
22
|
Park KH, Lee KH, Kim H and Hwang SO: The
anti-inflammatory effects of ulinastatin in trauma patients with
hemorrhagic shock. J Korean Med Sci. 25:128–134. 2010. View Article : Google Scholar
|
|
23
|
Gao CJ, Huan JN, Li W and Tang JJ:
Protective effects of ulinastatin on pancreatic and renal damage in
rats following early scald injury. Burns. 35:547–552. 2009.
View Article : Google Scholar
|
|
24
|
Larsen C, Ostergaard J, Larsen SW, Jensen
H, Jacobsen S, Lindegaard C and Andersen PH: Intra-articular depot
formulation principles: role in the management of postoperative
pain and arthritic disorders. J Pharm Sci. 97:4622–4654. 2008.
View Article : Google Scholar
|
|
25
|
Ning XH, Ge XF, Cui Y and An HX:
Ulinastatin inhibits unilateral ureteral obstruction-induced renal
interstitial fibrosis in rats via transforming growth factor β
(TGF-β)/Smad signalling pathways. Int Immunopharmacol. 15:406–413.
2013. View Article : Google Scholar
|
|
26
|
Inoue K, Takano H, Yanagisawa R, Sakurai
M, Shimada A, Yoshino S, Sato H and Yoshikawa T: Protective role of
urinary trypsin inhibitor in acute lung injury induced by
lipopolysaccharide. Exp Biol Med (Maywood). 230:281–287. 2005.
View Article : Google Scholar
|
|
27
|
Tanaka R, Fujita M, Tsuruta R, Fujimoto K,
Aki HS, Kumagai K, Aoki T, Kobayashi A, Izumi T, Kasaoka S, et al:
Urinary trypsin inhibitor suppresses excessive generation of
superoxide anion radical, systemic inflammation, oxidative stress,
and endothelial injury in endotoxemic rats. Inflamm Res.
59:597–606. 2010. View Article : Google Scholar
|
|
28
|
Molor-Erdene P, Okajima K, Isobe H, Uchiba
M, Harada N and Okabe H: Urinary trypsin inhibitor reduces
LPS-induced hypotension by suppressing tumor necrosis factor-alpha
production through inhibition of Egr-1 expression. Am J Physiol
Heart Circ Physiol. 288:H1265–H1271. 2005. View Article : Google Scholar
|
|
29
|
Park KJ, Oh YT, Kil WJ, Park W, Kang SH
and Chun M: Bronchoalveolar lavage findings of radiation induced
lung damage in rats. J Radiat Res. 50:177–182. 2009. View Article : Google Scholar
|
|
30
|
Anscher MS, Kong FM, Andrews K, Clough R,
Marks LB, Bentel G and Jirtle RL: Plasma transforming growth factor
beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol
Biol Phys. 41:1029–1035. 1998. View Article : Google Scholar
|
|
31
|
Chen G and Goeddel DV: TNF-R1 signaling: A
beautiful pathway. Science. 296:1634–1635. 2002. View Article : Google Scholar
|
|
32
|
Ghosh S, May MJ and Kopp EB: NF-kappa B
and Rel proteins: Evolutionarily conserved mediators of immune
responses. Ann Rev Immunol. 16:225–260. 1998. View Article : Google Scholar
|
|
33
|
Cox RA, Burke AS, Jacob S, Oliveras G,
Murakami K, Shimoda K, Enkhbaatar P, Traber LD, Herndon DN, Traber
DL and Hawkins HK: Activated nuclear factor kappa B and airway
inflammation after smoke inhalation and burn injury in sheep. J
Burn Care Res. 30:489–498. 2009. View Article : Google Scholar
|
